«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

23卷

期数:

2017年03期

页码:

227-230

栏目:

临床医学

出版日期:

2017-05-18

文章信息/Info

Title:

Relationship of cystatin c and CHA2DS2-VASc score in non-valvular atrial fibrillation patients

文章编号:

1006-8147(2017)03-0227-04

作者:

韩聪聪; 李姮; 郭兴梅; 王东昕; 任焘君; 徐延敏

(天津医科大学第二医院心脏科 ,天津 300211)

Author(s):

HAN Cong-cong; LIHeng; GUO Xing-mei; WANG Dong-xin; REN Tao-jun; XU Yan-min

(Department of Cardiology ,The Second Hospital ，Tianjin Medical University, Tianjin 300211,China)

关键词:

非瓣膜性心房颤动; 血清胱抑素c; CHA2DS2-VASc评分; 缺血性脑卒中

Keywords:

cystatin c ; non-valvular atrial fibrillation;  CHA2DS2-VASc score;  ischemic stroke

' target="_blank" rel="external">" />

分类号:

R541,7+5

DOI:

-

文献标志码:

A

摘要:

目的：探讨血清胱抑素C（CYS-c）与评估非瓣膜性房颤患者发生缺血性脑卒中风险的CHA2DS2-VASc评分的相关性。方法：连续入选非瓣膜性房颤患者99例（其中阵发房颤患者51例，持续房颤患者22例,永久性房颤患者26例），根据患者CHA2DS2-VASc评分，分为中低危组（CHA2DS2-VASc<2分者），高危组（CHA2DS2-VASc≥2分者），记录所有患者临床资料、实验室检查结果及超声心动图结果,比较两组各项指标的差异，同时探讨房颤患者血清胱抑素c与CHA2DS2-VASc评分的关系。结果：高危组的年龄、女性比例及伴有高血压、糖尿病、心力衰竭史、脑卒中史比例较中低危组显著升高，差异有统计学意义（P<0.05）。与中低危组相比，高危组患者血清胱抑素c、左房直径、中性粒淋巴细胞比值显著升高，差异有统计学意义（P<0.05）。多变量Logistic回归分析显示胱抑素c是房颤患者CHA2DS2-VASc的独立预测因素（P<0.05）。预测CHA2DS2-VASc高分的胱抑素c的ROC曲线下面积为0.722 (95%CI: 0.604-0.839, P<0.05)。结论：血清胱抑素c是非瓣膜性房颤患者CHA2DS2-VASc评分的独立预测因子，对房颤脑卒中风险评估有参考意义。

Abstract:

?Objective: To investigate the relationship between cystatinc(CYS-c)and CHA2DS2-VASc score for the evaluation of thromboembolism risk in patients with non-valvular atrial fibrillation(AF). MethodS: Ninety-nine patients with AF(51 with paroxysmal AF,22 with persistent AF and 21 with permanent AF)were collected in this study.According to CHA2DS2-VASc score,the AF patients were divided into low-intermediate risk group(CHA2DS2-VASc<2) and high risk group (CHA2DS2-VASc≥2). The clinical data, laboratory parameters and echocardiography were detected and then the parameters between the two groups were compared to evaluate the relationship between CYS-c and CHA2DS2-VASc score in patients with AF. Results: The basic characteristics between the two groups had significant differences in sex,age,and comorbidities.High CHA2DS2-VASc score group had higher CYS-c,left atrial diameter,and neutrophil lymphocyte ratio,when compared with the low CHA2DS2-VASc score group.The multivariate logistic regression analysis was performed to predict high CHA2DS2-VASc scores.The result revealed that CYS-c was an independent predictor (P<0.05).The area below the receiver-operating characteristic curve of CYS-c was 0.722(95%CI:0.604-0.839,P<0.05) for predicting high CHA2DS2-VASc score. Conclusion:CYS-c is an independent predictor for high CHA2DS2-VASc score and might provide some indications for the evaluation of thromboembolism.

参考文献/References:

[1] Miyasaka Y, Barnes M E, Gersh B J, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence[J]. Circulation, 2006,114(2):119

[2] Ni L, Lu J, Hou L B, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese[J]. Stroke, 2007,38(12):3287

[3] Uz O, Atalay M, Dogan M, et al. The CHA2DS2-VASc score as a predictor of left atrial thrombus in patients with non-valvular atrial fibrillation[J]. Med Princ Pract, 2014,23(3):234

[4] Camm A J, Kirchhof P, Lip G Y, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2010,31(19):2369

[5] Acet H, Ertas F, Akil M A, et al. New inflammatory predictors for non-valvular atrial fibrillation: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio[J]. Int J Cardiovasc Imaging, 2014,30(1):81

[6] Lip G Y, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest, 2010,137(2):263

[7] Tanaka K, Yamada T, Torii T, et al. Pre-admission CHADS2, CHA2DS2-VASc, and R2CHADS2 scores on severity and functional outcome in acute ischemic stroke with atrialfibrillation[J]. J Stroke Cerebrovasc Dis, 2015,24(7):1629

[8] Taillandier S, Olesen J B, Clementy N, et al. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study[J]. J Cardiovasc Electrophysiol, 2012,23(7):708

[9] 李丽萍, 张会琴, 温洪军, 等. 血清胱抑素C检测的临床价值[J]. 中国现代医学杂志, 2011(10):1229

[10] Wetmore J B, Mahnken J D, Rigler S K, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients[J]. Kidney Int, 2012,81(5):469

[11] Piccini J P, Stevens S R, Chang Y, et al. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"[J]. Circulation, 2013,128(11):e172

[12] Singer D E, Chang Y, Borowsky L H, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score[J]. J Am Heart Assoc, 2013,2(3):e250

[13] Apostolakis S, Guo Y, Lane D A, et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial[J]. Eur Heart J, 2013,34(46):3572

[14] Hijazi Z, Hohnloser S H, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial[J]. JAMA Cardiol, 2016,1(4):451

[15] Maccallum P K, Mathur R, Hull S A, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study[J]. BMJ Open, 2013,3(9):e3343

[16] Lind M, Jansson J H, Nilsson T K, et al. Cystatin C and creatinine as markers of bleeding complications, cardiovascular events and mortality during oral anticoagulant treatment[J]. Thromb Res, 2013,132(2):e77

[17] 刘萍, 罗本燕, 张筱英. 急性脑梗死患者血清胱抑素C水平与房颤的相关性[J]. 中国神经精神疾病杂志, 2012,38(12):720

[28] Bengtsson E, To F, Hakansson K, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice[J]. Arterioscler Thromb Vasc Biol, 2005,25(10):2151

相似文献/References:

备注/Memo

备注/Memo:

作者简介 韩聪聪(198-)，女，硕士在读，研究方向:心血管内科;

通信作者：徐延敏，E-mail: xuyanminphd@aliyun.com。

常用功能

更新日期/Last Update: 2017-05-18